Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I understand pump and dumps very well. I followed this stock closely when it was called KBIO. A poster child of pump and dumps. Then they changed name and brought in a real pro at pump and dump by dilution Cameron Durrant who just about ruined Anavex prior to 2014 by doing dilution stock offerings that allowed hedge funds to short the stock prior to being invited to by the stock at the secondary. The short selling is done with knowledge from the companies underwriters of the offering. The hedge funds are invited to participate in the offering and allowed to sell short with that inside knowledge. This is exactly what is happening in HGEN by the same CEO. That is a wall street dirty little secret but it is legal.
It may have been done to enrich favored hedge funds.
That lends evidence to my belief that that HGEN is an actual pump and dump scheme. The most telling is that the hedge funds buying the dilution stock offering were allowed to short HGEN stock before the offering with foreknowledge of the offering and after. So the secondary offerings allowed those hedge funds to cover short sales with shares issued at a lower price. Preplanned but unfortunately legal. Also these hedge fund buyers are free to continue to short the stock and will likely cover again at even lower prices in the next offering. That has been that HGEN's CEO's MOA at previous companies. A true pump and dump pro.
That lends evidence to my belief that the other company is an actual pump and dump scheme. The most telling is that the hedge funds buying the dilution stock offering were allowed to short that stock before the offering and after. So the secondary offerings allowed those hedge funds to cover short sales with shares issued at a lower price. Preplanned but unfortunately legal. Also these hedge fund buyers are free to continue to short the stock and will likely cover again at even lower prices in the next , offering. That has been that stock's CEO's MOA at previous companies. A true pump and dump pro.
CYDY should run to at least $20 IMO. But we just do not know when. If i can buy more at below $3 just means I can get more shares then if CYDY was trading at it's likely non suppressed and manipulated trading range of $4.50 to 7.50.
Well seeing where to stock it it is good to keep things light but I am always amazed at when long term believers complain about low share prices. Rejoice and buy more shares per dollars invested!
But since stock in on the floor might mean Phils before Brasils as Filipinos take coffee and tea sitting on the floor while Brazilians take coffee standing near an open door.
Thank you for this enlightening response. Much respect for all the knowledge you share with us here.
I was not joking and it was a reason I think Sanofi a traditionally large vaccine supplier should want to partner with CytoDyn to try its vaccinevyhat failed with the GlaxoSmithKline adjuvant as they are still trying new things to try to further develop this vaccine. This fits with what Dr Kelly said about BPs wanting to do trials with Leronlimab and a vaccine adjuvant is absolutely not something CytoDyn could do on its own. Using Leronlimab in vaccine trials is the most logical next step BUT it absolutely needs to be done by a BP already well into the development of the vaccine.
Sanofi or Merck who's vaccine also failed so far.
Maybe AZN needs to give the vaccine with a shot of Leronlimab?
It must be a Brazilian coffee cup because Filipino tea cups do not have handles.
There will be a licencing deal for Leronlimab in some indication. This is a fantastic drug and BP knows it. This last down drafts in the share price might be positioning to gather shares for accumulation by funds or covering buy shirt selling hedge funds.
The Battle has begun. The message is being relayed around The World. Grass roots are taking such a from hold that the Earth itself might tremble. You are correct in my opinion. These next twenty-eight Filipino patients could turn the tide of the Covid War. One brave platoon to spearhead a worldwide revolt against the tyranny of Covid.
Yes...don't blink. What happens next could be like a bolt of lightning from a clear blue sky so unexpected and so transformative; positively electrifying a planet in the grip of this pandemic. Not as much like a rocket to the moon but rather as being transported to Mars in the blink of an eye.
A BP partnership with CytoDyn would send a shock wave reverberating around the world and might knock some sense into World Drug Regulatory Agencies who have heretofore have been as ineffectual as a deer mesmerized by the headlights of the vehicle that ran it over.
Sanofi Pasteur
Let us hope that the rise of Leronlimab and the exposure of the ridiculous suppression of safe drugs in favor of the moneymakers of BP might also shine bright daylight beams on the travesty of an FDA in the pocket of Big Pharma.
And yet every man woman and soon to be children are being vaccinated with vaccines that are not approved but only have EUA. Novel types of vaccines that have never been approved for any other pathogen either. Vaccines that are called vaccines but are really not vaccines as they are designed not to prevent infection but to make the illness less sever. They have not been shown to prevent the illness or to prevent spread of the Covid just to increase survivability of the illness.
But totally safe therapeutics are being sidelines and held back like Ivermectin and Leronlimab, even Vitamin D is not recommended. Just masks and shut downs...if you get sick quarantine until you need to be hospitalized then you get worthless Remdesivir.
Yes that is right the Merck vaccine failed as well. The Pfizer and ModeRNA might end up failing after everyone gets the short on the new variants. Best vaccine might use Leronlimab as an adjuvant.
France could have use for Leronlimab. French BP Sanofi a big vaccine company has had setbacks in its Covid19 vaccine development. Sanofi is my from left field speculation.
Nader did answer why that in a way. He said if anyone is not doing their job or working fast enough they will be replaced.
From what I understand the mRNA shots from Pfizer and Moderns are not really vaccines and but are shots to "preprime" or modify the immunsystems to recognize and attack the Covid virus and are intended to make the course of illness less sever not to prevent infection. The J&J VACCINE I believe is more like a traditional vaccine.
Nope
9.5 million shares traded closed right near HOD up 25%. Technically CYDY is reaching critical mass for a further breakout. 200 dma $4.04 and still under 70% RSI. Looks like another stellar rise tomorrow.
Like I said Friday CYDY is hitting alot of radars. Professionals do not give weight to lawsuits based off of short sellers articles from SA, STAT News or anywhere else.
The courts see a lot of these baseless lawsuits.
I have noticed this lawsuit deluge in many potentially disruptive biotechs before going on to be 5 to 10 baggers within a year. For me it is a buy signal as I have always made at least 5x within 18 months and that was on more than a few. The last one was 20x at the peak even before approval.
95% of all those securities class actions are nuisance suits fishing for a settlement. They rarely amount to anything.
Up over 21% 3 million shares in first hour and a half. More than all day Last Friday on that big surge. Smart big money sees through the lawsuit filed based on a Short sellers article published in Seeking Alpha.
$5.06 CYDY does not enter the powerband at 70% RSI until over $5.06.
That should trigger buy/stops on many of the 30 million shares held short.
Time to Rock and Roll.
There are no FDA accepted cellular biomarkers for Covid19 except viral load and Leronlimab is not an antiviral. So what would they use advanced diagnostics to test for in the realm of a clinical trial?
These were important in the basic research and the incellDX tests performed that function so that CytoDyn felt confident to move from research into the clinical trials. If Leronlimab is approved then testing for these biomarkers might be important in further trials to expand the label. First they need to show it has efficacy then can show it might have further efficacy in other indications centering on the RANTES pathway.
IncellDX Dr. Patterson's company supplied diagnostic tests for Leronlimab research. These tests are powerful but novel and have not gained widespread use. Also they are comparatively expensive. CytoDyn decided to use another diagnostic vendor for the Covid clinical trials. No IncellDX tests in the trials then no Dr. Patterson in the trials.
It is a simple matter of wanting to use the standard accepted diagnostic tests in the clinical trials so the reliability of the diagnostics does not introduce another factor to bring the results into question.
This was a fairly straightforward business decision and a good one. It is unfortunate that the incellDX tools are so new as they are very good but not in widespread use yet. It is unfortunate that Dr Patterson did not come with the other vendors tests as he is super qualified. Hopefully in the future CytoDyn can contract with IncellDX on more advanced trials in other indications.
This was a clinical development decision not a personality clash in some imaginary soap opera drama.
Dr Patterson did a lot to advance Leronlimab. He deserves a lot of credit but he has already been paid for his contribution. Likely he will be open to further collaboration in the future as a contractor for CytoDyn.
For now CytoDyn is better off using the conventional diagnostics as they are more widely accepted and understood.
Everything about the trials has been normal and natural. Speed bumps are par for the course and are expected.
We got this! Be patient the science will prove out.
CYDY is now technically set up for a gap and surge up next week. RSI only 51%. Look at Jan 27 28 & 29. Observe those 3 days daily candles and compare with the last three days. I can unequivocally state many traders will notice this same thing by Mondays open. Jan 29 was a Friday on Mon Feb 1 it gapped up .20 to $5.77 then ran to $7.23 in one day. Today before a long weekend CYDY finished at HOD up 18.15%. This will hit a lot of traders radar over the weekend good surge backed with good fundamental news.
A similar move Monday to the Feb 1st move will see CYDY gap to $3.40s and surge to the $5.00 handle which should still be below 70% RSI and only to the midpoint of CYDY's longer term regression trading channel.
Strap in it should be a fun ride up next week.
Happy Easter and time to light the CYDY rocket engines.
Excellent post. I think your post more than adequately describes the process. Please forward your post to Dr Bruce Patterson for his comments and kindly report his response here to this board. Kudos!!!
This post rates maximum Good Karma.
Properly dosed with first dose IV then 3 more doses properly spaced Leronlimab is likely to give a efficacy signal on the order of NARCAN. Where all most all can recover.
A key tenent of technical trading is when a stock breaks out like CYDY did on a large spike 3-30 then a buy signal is generated on the consolidation pull back as happened on 3-31 which is a good place to add or take a position. CYDY should continue to break out to the upside.
If people take a depressive veiw of CYDY walking away will not bring relief as there will be another company to be depressed about. If one has no optimism one should look inward for the solution.
The Merck/Ridgeback drug is for the early viral stage. Leronlimab is for the later immunological cytokine storm phase. Not competition but possibly having both would be great to help in this pandemic.
Excellent DD posts. NOK is winning but it might be priced for failure.
You might want to get up to speed. Columbus has sailed. 14 days into a 21 to 35 day voyage, believing the earth is flat will not end the voyage.
No not US trained.
I believe there is a good probability that FDA grants an EUA within a month and that the CD16 and CD17 will be used to expand and focus the use of LL in Covid and possible full approval after these or further studies. What is needed is the knowledge of how best to use the drug and which patients respond the best. With more knowledge of how to dose for instance four shots, using with Dexamethasone ect. the efficacy will likely increase further. Advancing the protocols for the best patient outcomes. There is much to know still. CD10 and CD12 were early trials. The beginning studies not not the final studies. Most other drugs failed and were scrapped. Leronlimab is just getting started and continues to advance.
Why would anyone give credence or any weight whatsoever of biotech opinions of someone who does not know that the degrees of Medical Doctor and Doctor of Ostheopathy trained in the USA are equivalent and can be licenced to practice in all areas of Medicine.
That is just dumbdumbdumbdumb.
CytoDyn we got this!
https://www.fiercebiotech.com/biotech/gsk-fails-covid-19-phase-2-subgroup-finding-fuels-further-work
Umm...so looks like Glaxo failed its first trials GM-CSF drugs for Covid and going for subgroups.
CYDY is on a sure and steady path to approval and the conduct of further trials is a rational, normal, and natural way BPs approach clinical development as well.
Did not the GLAXO (BP) GM-CSF Covid drug recently fail is Covid19 trial?
Some good news on the regulatory front might cause a drastic upward revaluation of CYDY stock like what happened with Novavax. I will be holding and adding. With these volatile high reward Pre revenue biotechs it is somewhat like rodeo bull riding. One has to stay on for the full ride to get the trophy buckle and not get thrown off on the rapid twists and turns of the share price.
Recent example Anavex. Knocked down by AF and shirt reports, lawsuits, fire CEO ect. to $1.26 in Dec 2018 now trading at all time highs of $14.45 plus way before any approvals or even registration trial conclusions.
CYDY trophy buckle might be another ten bagger from here in a relatively near term time frame.
Emotional traders cause their own disasters.
CYDY Get them while they are hot. Much of the financial risk is squeezed out by the low share price. Much of the clinical risk is squeezed out by the knowledge learned in the completed trials to design Phase 3s for a greater chance of clinical success.